2023 Form 5500 filing — Kiniksa Pharmaceuticals 401(K) Plan

Plain-English filing summary

According to public Form 5500 filings published through the U.S. Department of Labor (DOL) Employee Benefits Security Administration (EBSA) via the EFAST2 system, this is the 2023 Form 5500 filing (EFAST2 acknowledgement 20240709101922NAL0015244961001) for Kiniksa Pharmaceuticals 401(K) Plan, reported by Kiniksa Pharmaceuticals Corp. under EIN 47-4596717 and plan number 001. It reports 364 participants. Attached schedules in the loaded dataset include Schedule H (large plan financials), Schedule C (service provider compensation).

EFAST2 acknowledgement
20240709101922NAL0015244961001
Filing year
2023
Form type
2
Plan sponsor
Kiniksa Pharmaceuticals Corp.
EIN
47-4596717
Plan number
001
Location
Lexington, MA
Participants
364
Schedules available
Schedule H, Schedule C
Received date
not reported in the loaded dataset

Reported financial snapshot (2023)

Total assets (EOY)
$27,920,065
Total liabilities (EOY)
$0
Net assets (EOY)
$27,920,065
Employer contributions
$2,105,617
Participant contributions
$4,289,519
Total income / additions
$11,145,867
Benefits paid
$1,835,256
Administrative expenses
$69,187
Total expenses
$1,907,153
Net increase / (decrease)
$9,238,714
Schedule source
Schedule H

Reported service provider compensation (Schedule C)

Compensation reported on the 2023 filing
ProviderServiceDirect comp.Indirect comp.
Fidelity Investments InstitutionalRECORDKEEPER$30,572not reported in the loaded dataset
Captrust Financial AdvisorsINVESTMENT ADVISOR$24,599not reported in the loaded dataset
Strategic Advisors, Inc.ADVISOR$10,614not reported in the loaded dataset

Related Form 5500 pages